(Q46063609)

19 December 2017

title

Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis (English)

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

1 November 2022

0 references

1 reference

7

R. B. Moss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

author name string

J. E. Van Wye

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

M. S. Collins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

M. Baylor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

J. E. Pennington

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

Y. P. Hsu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

V. Sampanvejsopa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1697059

1 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1697059

1 November 2022

publication date

1 January 1990

1 reference

19 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fppul.1950090104

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

https://onlinelibrary.wiley.com/doi/full/10.1002/ppul.1950090104

1 November 2022

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

1 November 2022

published in

Pediatric Pulmonology

1 reference

19 December 2017

volume

9

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

7-18

1 reference

19 December 2017

Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.1950090104

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.1950090104

Mechanism for pulmonary protection by lipopolysaccharide pseudomonas vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.1950090104

Human Immunity to Pseudomonas aeruginosa. II. Relationship between Heat-Stable Opsonins and Type-Specific Lipopolysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.1950090104

Intravenous immunoglobulins as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.1950090104

Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients.

1 November 2022

3

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum

1 November 2022

4

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis

1 November 2022

5

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency.

1 November 2022

7

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses

1 November 2022

8

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo

1 November 2022

10

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis

1 November 2022

11

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa

1 November 2022

12

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Interobserver variance in clinical scoring for cystic fibrosis

1 November 2022

13

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

1 November 2022

14

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection

1 November 2022

15

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity

1 November 2022

19

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal

1 November 2022

24

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis

1 November 2022

25

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Cephalosporin therapeutics in cystic fibrosis

1 November 2022

26

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Antibiotic therapy in cystic fibrosis: evaluation of clinical trials

1 November 2022

27

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.

1 November 2022

28

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Intravenous immune globulin for hypogammaglobulinemia: a comparison of opsonizing capacity in recipient sera

1 November 2022

31

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

1 November 2022

33

41

903

Williams

1980

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Opsonic defect in patients with cystic fibrosis of the pancreas

1 November 2022

35

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages

1 November 2022

37

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Phagocytosis of Pseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum.

1 November 2022

39

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Correlation of serum opsonic activity in cystic fibrosis with colonization and disease state: measurement of opsonins to Pseudomonas aeruginosa by neutrophil superoxide anion generation

1 November 2022

41

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

1 November 2022

42

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

1 November 2022

43

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients

1 November 2022

44

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages

1 November 2022

46

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients

1 November 2022

47

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains

1 November 2022

48

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis

1 November 2022

49

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Human IgG antibodies to Pseudomonas aeruginosa core lipopolysaccharide determinants are detected in chronic but not acute pseudomonas infection

1 November 2022

54

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

Intravenous immunoglobulin therapy. New directions and unanswered questions

1 November 2022

55

1 reference

https://api.crossref.org/works/10.1002/PPUL.1950090104

1 November 2022

Identifiers

1 reference

19 December 2017

1 reference

19 December 2017